Investment Focus - The report highlights Amazon (AMZN US) as a top pick due to its leading position in the cloud industry with a 30% global market share, stable margin improvements, and strong demand for its T3 inference capabilities [1] - Alphabet (GOOGL US) is favored for its AI and advertising synergy, expected margin improvements in IaaS cloud services, and strong self-developed capabilities, although its stock price upside is currently limited [1] - Arista (ANET US) is recognized for its leadership in high-speed data center switches and expected revenue contributions from AI backend switch business, with a significant growth visibility [1] - Meituan (3690 HK) is noted for its strong cash flow generation ability and competitive cost structure, positioning it well in the face of industry competition [1] - Lenovo (992 HK) is highlighted for its record revenue in AI server business and significant growth potential compared to peers like Dell [2] - NVIDIA (NVDA US) is recognized for its strong financial performance and technological leadership in data center business, with a focus on emerging applications driving growth [2] - Tencent (700 HK) is expected to benefit significantly from AI advancements, with an upward revision in revenue and profit expectations for 2025 [2] - New Oriental (EDU US) is noted for its diverse revenue sources and strong brand recognition, supporting its high profit margins [3] - AIA (1299 HK) is favored for its steady growth in new business value and strong operational metrics, particularly in the ASEAN market [3] - Futu (FUTU US) is expected to see significant growth in paid user numbers and total AUM, supported by its low commission model and quality customer service [3] - The report emphasizes the potential of Chinese pharmaceutical companies like China Biologic Products (1177 HK) and Innovent Biologics (1801 HK) in their innovative drug pipelines and market leadership [4]

Market Capitalization Summary - New Oriental has a market capitalization of 16.359 billion [2] - TAL Education has a market capitalization of 10.938 billion [2] - Vipshop has a market capitalization of 6.578 billion [2] - Miniso has a market capitalization of 5.578 billion [2] - Zai Lab has a market capitalization of 3.982 billion [2] - Huya has a market capitalization of 0.724 billion [3] Stock Performance - New Oriental's stock increased by 0.77 (+3.89%) [2] - TAL Education's stock decreased by 0.04 (-0.82%) [2] - Vipshop's stock decreased by 0.18 (-1.19%) [2] - Miniso's stock decreased by 0.50 (-2.62%) [2] - Zai Lab's stock decreased by 1.95 (-5.16%) [2] - Huya's stock increased by 0.01 (+0.45%) [3] Additional Company Insights - Financial One Account has a market capitalization of 0.287 billion [3] - Xiaomi has a market capitalization of 0.213 billion [3] - Huami has a market capitalization of 0.175 billion [3] - Tuniu has a market capitalization of 0.120 billion [3]

资料显示，新氧国际公司是一家致力于用科技的方式帮助爱美女性健康变美的公司。创始人成立了新 氧,通过提供透明的信息,改变中国快速增长但不透明的医学美学市场,最终使他们能够建立一个一站式的 平台,用户可以方便地找到优质的服务。 本文源自：金融界 作者：行情君 8月1日，新氧(SY)盘中上涨5.06%，截至21:41，报4.675美元/股，成交67.27万美元，总市值4.69亿美 元。 财务数据显示，截至2025年03月31日，新氧收入总额2.97亿人民币，同比减少6.6%；归母净利润-3313.8 万人民币，同比减少56.02%。 大事提醒： 8月15日，新氧将于(美东)盘前披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 ...

Market Capitalization Overview - New Oriental has a market capitalization of 15.747 billion [2] - TAL Education (好未来) has a market capitalization of 11.040 billion [2] - Vipshop (唯品会) has a market capitalization of 9.610 billion [2] - Miniso (名创优品) has a market capitalization of 5.940 billion [2] - Zai Lab (再鼎医药) has a market capitalization of 4.200 billion [2] - Huya (虎牙) has a market capitalization of 7.500 billion [2] Stock Performance - New Oriental's stock increased by 0.36 (+8.09%) [2] - TAL Education's stock decreased by 0.27 (-0.60%) [2] - Vipshop's stock increased by 0.56 (+2.49%) [2] - Miniso's stock increased by 0.01 (+0.07%) [2] - Zai Lab's stock decreased by 0.81 (-4.06%) [2] - Huya's stock increased by 0.03 (+0.75%) [2] Additional Company Insights - Financial One Account (金融壹账通) has a market capitalization of 2.91 million [3] - Xunlei (迅雷) has a market capitalization of 4.48 million [3] - Huami Technology (华米科技) has a market capitalization of 1.64 million [3] - Tuniu (途牛) has a market capitalization of 1.21 million [3] - Aiqiyi (爱奇艺) has a market capitalization of 24.11 billion [2]

Core Viewpoint - The Chinese cosmetic medical industry is transitioning from "wild growth" to "quality stratification," with rapid technological advancements, clearer regulatory frameworks, and increasing consumer sensitivity to safety and pricing. The ability to achieve "standardized delivery + brand mindset + deep industry chain" will define the next decade's game rules [1]. Group 1: Business Structure and Expansion - New Oxygen has reached a significant milestone with 31 stores, becoming the largest chain in China's light medical beauty sector, with chain business revenue becoming the largest source of income for the group [1][2]. - The company is exploring whether the current high gross margin and low net profit phenomenon in the medical beauty industry can be fundamentally changed through strategic expansion and business model transformation [2]. Group 2: Market Positioning and Target Audience - The target demographic for New Oxygen is primarily the middle class, with an annual income around 100,000 yuan and a medical beauty budget of approximately 15,000 yuan, focusing on women aged 30 to 40 [22]. - The company aims to make medical beauty accessible to a broader audience, similar to the model of Sam's Club, by providing high-quality services at competitive prices [21][25]. Group 3: Operational Strategy and Differentiation - New Oxygen employs a strict recruitment process for doctors, categorizing them by skill level to ensure high-quality service delivery for standardized medical beauty procedures [24]. - The company emphasizes digital management over traditional human management to efficiently scale its operations, aiming for over 1,000 stores in the long term [26][28]. Group 4: Industry Challenges and Competitive Landscape - The medical beauty industry in China is highly fragmented, with over 20,000 institutions, where the majority are small, single-location clinics. New Oxygen's 31 stores represent a significant achievement in a market dominated by small players [26][27]. - The company faces challenges from traditional medical beauty institutions that have historically focused on high-end clientele, making it difficult to standardize services across the industry [27]. Group 5: Vertical Integration and Supply Chain Management - New Oxygen is pursuing vertical integration within the medical beauty industry, aiming to control both upstream and downstream operations to enhance cost efficiency and service quality [35][36]. - The company believes that true innovation often comes from cross-industry collaboration, which can lead to better product integration and customer experience [36]. Group 6: Future Aspirations and Personal Reflections - The CEO expresses a desire to build a widely recognized brand with a strong public reputation, indicating that the journey is ongoing and that there is still much to achieve [39]. - The company aims to balance idealism with practical business considerations, focusing on creating value for consumers while ensuring profitability [19].

Group 1: Baby and Childcare Sector - The baby and childcare concept stocks mostly opened higher, with notable increases in shares of companies such as Jinxin Reproductive Medicine (1951.HK) up 8.93%, H&H International Holdings (1112.HK) up 7.33%, and China Feihe (6186.HK) up 5.12% following the announcement of a new childcare subsidy policy [1] - The new policy, effective from January 1, 2025, provides an annual subsidy of 3,600 yuan for each child until they reach three years old, which is expected to boost the sector [1] Group 2: Pharmaceutical Sector - WuXi AppTec (2359.HK) opened over 4% higher after reporting a revenue of 20.799 billion yuan for the six months ending June 30, 2025, a year-on-year increase of 20.6%, with a net profit of 8.287 billion yuan, up 95.5% [1] - Fosun Pharma (2196.HK) saw a 1.37% increase after signing a licensing agreement for AR1001, aimed at treating Alzheimer's disease and other neurological disorders [2] - Deqi Pharmaceutical (6996.HK) rose 4.70% after receiving approval for a new indication of its drug, Xivio, for treating multiple myeloma [2] - Kangzheng Pharmaceutical (0867.HK) increased over 2% after announcing the acceptance of its new drug application for ZUNVEYL, aimed at treating Alzheimer's symptoms [4] - BeiGene (6160.HK) rose over 3% following a positive recommendation from the European Medicines Agency for its drug, Tislelizumab, for non-small cell lung cancer [4] Group 3: Automotive Sector - Hong Kong automotive dealer stocks rose, with Zhongsheng Holdings (0881.HK) up nearly 6% and Yongda Automotive (3669.HK) up over 4%, driven by expectations of improved profit margins from new car sales due to government policies [2] - UBS reported that Zhongsheng and Yongda's stock prices rebounded approximately 20% and 5% respectively, as the market anticipates industry consolidation and improved profitability [2] Group 4: Beverage Sector - Hong Kong Brewery (0236.HK) surged 26% after reporting a revenue of approximately 390 million HKD for the first half of 2025, a year-on-year increase of 3.22%, with a net profit of 49.644 million HKD, up 31.97% [3] Group 5: Securities Sector - Chinese brokerage stocks collectively declined, with Shenwan Hongyuan (6806.HK) down nearly 5%, amid tightening regulatory scrutiny in the securities industry, which has seen over 30 fines issued recently [3]

Market Capitalization Summary - New Oriental has a market capitalization of 15.943 billion [2] - TAL Education has a market capitalization of 10.927 billion [2] - Vipshop has a market capitalization of 9.612 billion [2] - NIN (Miniso) has a market capitalization of 5.940 billion [2] - JD.com has a market capitalization of 27.23 billion [2] - iQIYI has a market capitalization of 2.548 billion [2] Stock Performance - New Oriental's stock decreased by 0.35 (-1.75%) [2] - TAL Education's stock decreased by 0.10 (-1.93%) [2] - Vipshop's stock decreased by 0.53 (-2.25%) [2] - Miniso's stock increased by 0.64 (+1.36%) [2] - JD.com's stock decreased by 0.54 (-3.42%) [2] - iQIYI's stock decreased by 0.07 (-2.31%) [2] Additional Company Insights - Huami Technology has a market capitalization of 1.97 billion [3] - Cheetah Mobile has a market capitalization of 1.63 billion [3] - Baosheng E-commerce has a market capitalization of 1.84 billion [3] - Tuniu has a market capitalization of 1.34 billion [3] - The stock of Tuniu increased by 0.42 (+4.60%) [3]

Core Viewpoint - So-Young International Inc. is set to report its financial results for Q2 2025 on August 15, 2025, highlighting its position as a leading aesthetic treatment platform in China [1]. Company Overview - So-Young International Inc. operates as the leading aesthetic treatment platform in China, connecting consumers with both online services and offline treatments [4]. - The company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, and delivering high-quality treatments [4]. - So-Young is involved in the development, production, and distribution of optoelectronic medical equipment and injectable products, positioning itself well for long-term growth in the medical aesthetic value chain [4]. Earnings Conference Call - The management will hold an earnings conference call on August 15, 2025, at 7:30 AM U.S. Eastern Time, with dial-in details provided for international and local participants [2]. - A telephone replay of the conference call will be available two hours after its conclusion until August 22, 2025 [3].

Summary of Key Points from Conference Call Records Industry Overview - The conference call primarily discusses the medical aesthetics (医美) industry and related companies, including New Oxygen (新氧), Love Beauty (爱美客), and others in the beauty and healthcare sectors. Core Insights and Arguments 1. **New Oxygen's Business Model**: New Oxygen is leveraging standardized projects and private traffic to reduce costs and attract price-sensitive consumers. However, the increasing demand for high-end projects may raise costs for doctors, posing a challenge for the company's long-term strategy [8][9][11]. 2. **Impact of Market Sentiment**: Runben's stock price rebounded nearly 30% due to market sentiment influenced by the outbreak of diseases in Foshan, despite limited actual sales impact [1][3]. 3. **Acquisition Benefits for Love Beauty**: Love Beauty's acquisition of Region and obtaining the agency rights for Isophane in China has significantly boosted its stock price, with expected profit contributions of over 450 million yuan in the coming year [1][20]. 4. **Challenges for Juzi Biotechnology**: Juzi's sales have declined due to public sentiment issues, leading to a drop in valuation. The recovery of sales through influencer marketing will be crucial for its stock price rebound [1][4][31]. 5. **LePu Medical's Performance**: LePu's main business is affected by centralized procurement, but its medical aesthetics segment is progressing well, with expected revenue contributions from new products [1][13]. 6. **Market Dynamics**: The medical aesthetics industry is experiencing increased competition and price wars, driven by the entry of new products and the need for traditional institutions to adapt to New Oxygen's model [10][12]. Additional Important Insights 1. **Digital Transformation in Beauty Sector**: Companies like Beautiful Farm are enhancing business uniformity and customer acquisition costs through digital systems and training, positioning themselves for growth [2][17]. 2. **Emerging Trends in Marketing**: The rise of short videos and live-streaming as marketing channels is reshaping how brands engage with younger consumers, necessitating innovative strategies [6][8]. 3. **Regulatory Changes**: New regulations on advertising may impact smaller brands more significantly than larger listed companies, potentially improving the competitive landscape for established players [23]. 4. **Future Outlook for Companies**: Companies like Beautiful Farm and Love Beauty are expected to see significant growth due to strategic acquisitions and market positioning, while others like Juzi may need to recover from recent setbacks [17][20][31]. This summary encapsulates the key points discussed in the conference call, highlighting the dynamics within the medical aesthetics industry and the performance outlook for various companies involved.

Investment Rating - The report initiates coverage with an OUTPERFORM rating for the company, with a target price of $10.10, compared to the current price of $5.87 [3][4]. Core Insights - The company is positioned in the burgeoning light medical aesthetics industry in China, benefiting from increasing consumer demand for beauty and anti-aging solutions, a diverse range of upstream products, and improving industry standards and transparency [4][5]. - Despite a significant stock price increase of 487% since mid-June, the company is expected to continue its upward trajectory due to rapid expansion and substantial growth potential [4][6]. Company Overview - The company, So-Young (SY US), is a leading medical aesthetics service group in China and the first online medical aesthetics service platform listed on NASDAQ, established in 2013 [10]. - As of January 2024, the platform has onboarded 57,464 certified institutions and 43,771 physicians, with over 630 million beauty diaries and 210 million downloads [10][11]. Market Overview - The light medical aesthetics market in China is projected to grow at a CAGR of 16.3%, reaching RMB 339 billion by 2030, driven by increased consumer awareness and a diverse product supply [5][32]. - The market remains highly fragmented, with a significant opportunity for chain institutions to increase their penetration due to the standardized nature of light medical aesthetics projects [5][41]. Competitive Advantages - The company aims to address industry pain points such as information asymmetry and high customer acquisition costs through its supply chain advantages and digital marketing capabilities [6][47]. - The rapid expansion of the company's clinics, from 1 in May 2023 to 32 by mid-2025, showcases its strong execution capabilities and ambition to reach 1,000 clinics in the next 7-8 years [6][58]. Financial Analysis and Forecast - Revenue is projected to grow from RMB 1.47 billion in 2024 to RMB 2.68 billion in 2026, with a significant increase in net profit expected in 2026 [3][4]. - The company’s traditional POP business is expected to stabilize, contributing positive cash flow, while the medical aesthetics segment is anticipated to become a new growth driver [7][12]. Valuation and Recommendations - The report employs a segmented valuation approach, assigning different P/E ratios to various business segments, resulting in a target price of $10.10 [7][4]. - The company is expected to maintain a competitive edge through its cost-effective operations and strong digital capabilities, with a projected net profit margin improvement to 20% in the future [7][78].